Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 4 3Phase NA 1Phase 1/2 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 2NIH 2INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 15Other hematologic neoplasm 8Dermatologic 5Gynecologic 2Myeloid 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 4Sezary Syndrome 1Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Kidney Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Renal Cell 1

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19Mycophenolic Acid 19HhAntag691 19Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × denileukin diftitox × Dermatologic × Clear all
NCT01127451 2022-04-13

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Eisai Inc.

Phase 2 Completed
75 enrolled 15 charts
Dermatologic

Melanoma, Neoplasms

NCT00515528 2021-01-26

Vaccination Plus Ontak in Patients With Metastatic Melanoma

University of Chicago

Phase 2 Terminated
17 enrolled 7 charts
Dermatologic

Melanoma

NCT00299689 2014-09-05

Phase II Trial of Ontak With Metastatic Melanoma

James Graham Brown Cancer Center

Phase 2 Completed
69 enrolled 3 charts
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00082914 2013-06-20

Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

NCT00006345 2013-05-30

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡